Theralase Technologies Inc
XTSX:TLT
Theralase Technologies Inc
XTSX:TLT
Price:
0.265
CAD
-1.85%
Market Closed
Market Cap:
CA$68.1m
Relative Value
The Relative Value of one
TLT
stock under the Base Case scenario is
0.137
CAD.
Compared to the current market price of 0.265 CAD,
Theralase Technologies Inc
is
Overvalued by 48%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
TLT
Relative Value
Base Case
0.137
CAD
Overvaluation 48%
Multiples Across Competitors
TLT Competitors Multiples
Theralase Technologies Inc Competitors
Theralase Technologies Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
Theralase Technologies Inc
XTSX:TLT
|
68.1m CAD | 68.1 | -15.6 | -16.5 | -15.5 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
195.6B USD | 4.4 | 30 | 17.2 | 23.6 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
175.3B USD | 17.4 | 61.4 | 46.6 | 57.3 | |
| US |
|
Stryker Corp
NYSE:SYK
|
140B USD | 5.6 | 43.1 | 21.9 | 26.5 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
117.2B USD | 3.3 | 25.4 | 13.9 | 20.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
106.6B USD | 5.3 | 36.8 | 21.6 | 28.9 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
45.7B EUR | 2 | 21.5 | 11.9 | 16.8 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 8.1 | 45.6 | 25.1 | 27.5 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
48.7B USD | 11.3 | 45.9 | 32.6 | 36.1 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
47.1B USD | 2.1 | 26.8 | 10.5 | 17.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
36.8B USD | 6.8 | 24.8 | 17.5 | 19.5 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
